SrasV1, PubMed, Corpus, bibRecord, 000065

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Identifieur interne : 000065 ( PubMed/Corpus ); précédent : 000064; suivant : 000066

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Auteurs : Nicholas D. Brownstone ; Quinn G. Thibodeaux ; Vidhatha D. Reddy ; Bridget A. Myers ; Stephanie Y. Chan ; Tina Bhutani ; Wilson Liao

Source :

Dermatology and therapy [ 2193-8210 ] ; 2020.

RBID : pubmed:32300516

Abstract

With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.

DOI: 10.1007/s13555-020-00377-9
PubMed: 32300516

Links to Exploration step

pubmed:32300516

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.</title>
<author><name sortKey="Brownstone, Nicholas D" sort="Brownstone, Nicholas D" uniqKey="Brownstone N" first="Nicholas D" last="Brownstone">Nicholas D. Brownstone</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thibodeaux, Quinn G" sort="Thibodeaux, Quinn G" uniqKey="Thibodeaux Q" first="Quinn G" last="Thibodeaux">Quinn G. Thibodeaux</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Reddy, Vidhatha D" sort="Reddy, Vidhatha D" uniqKey="Reddy V" first="Vidhatha D" last="Reddy">Vidhatha D. Reddy</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Myers, Bridget A" sort="Myers, Bridget A" uniqKey="Myers B" first="Bridget A" last="Myers">Bridget A. Myers</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chan, Stephanie Y" sort="Chan, Stephanie Y" uniqKey="Chan S" first="Stephanie Y" last="Chan">Stephanie Y. Chan</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bhutani, Tina" sort="Bhutani, Tina" uniqKey="Bhutani T" first="Tina" last="Bhutani">Tina Bhutani</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liao, Wilson" sort="Liao, Wilson" uniqKey="Liao W" first="Wilson" last="Liao">Wilson Liao</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32300516</idno>
<idno type="pmid">32300516</idno>
<idno type="doi">10.1007/s13555-020-00377-9</idno>
<idno type="wicri:Area/PubMed/Corpus">000065</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000065</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.</title>
<author><name sortKey="Brownstone, Nicholas D" sort="Brownstone, Nicholas D" uniqKey="Brownstone N" first="Nicholas D" last="Brownstone">Nicholas D. Brownstone</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Thibodeaux, Quinn G" sort="Thibodeaux, Quinn G" uniqKey="Thibodeaux Q" first="Quinn G" last="Thibodeaux">Quinn G. Thibodeaux</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Reddy, Vidhatha D" sort="Reddy, Vidhatha D" uniqKey="Reddy V" first="Vidhatha D" last="Reddy">Vidhatha D. Reddy</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Myers, Bridget A" sort="Myers, Bridget A" uniqKey="Myers B" first="Bridget A" last="Myers">Bridget A. Myers</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Chan, Stephanie Y" sort="Chan, Stephanie Y" uniqKey="Chan S" first="Stephanie Y" last="Chan">Stephanie Y. Chan</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Bhutani, Tina" sort="Bhutani, Tina" uniqKey="Bhutani T" first="Tina" last="Bhutani">Tina Bhutani</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Liao, Wilson" sort="Liao, Wilson" uniqKey="Liao W" first="Wilson" last="Liao">Wilson Liao</name>
<affiliation><nlm:affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</nlm:affiliation>
</affiliation>
</author>
</analytic>
<series><title level="j">Dermatology and therapy</title>
<idno type="ISSN">2193-8210</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass></textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">32300516</PMID>
<DateRevised><Year>2020</Year>
<Month>04</Month>
<Day>20</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8210</ISSN>
<JournalIssue CitedMedium="Print"><PubDate><Year>2020</Year>
<Month>Apr</Month>
<Day>16</Day>
</PubDate>
</JournalIssue>
<Title>Dermatology and therapy</Title>
<ISOAbbreviation>Dermatol Ther (Heidelb)</ISOAbbreviation>
</Journal>
<ArticleTitle>Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.</ArticleTitle>
<Pagination><MedlinePgn>1-11</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1007/s13555-020-00377-9</ELocationID>
<Abstract><AbstractText>With the emergence of the novel coronavirus disease (COVID-19) viral pandemic, there is uncertainty whether biologic agents for psoriasis may place patients at a higher risk for infection or more severe disease course. This commentary offers patient counseling recommendations based on the current available evidence. While there are currently no specific data for psoriasis biologics and COVID-19, data are presented here from phase III clinical trials of psoriasis biologics on rates of upper respiratory infection, influenza, and serious infection. Overall these data reveal that on the whole, psoriasis biologics do not show major increases in infection risk compared to placebo during the course of these trials. However, as the COVID-19 virus is a novel pathogen that is associated with mortality in a subset of patients, a cautious approach is warranted. We discuss factors that may alter the benefit-risk ratio of biologic use during this time of COVID-19 outbreak. Ultimately, treatment decisions should be made on the basis of dialogue between patient and provider, considering each patient's individualized situation. Once this pandemic has passed, it is only a matter of time before a new viral disease reignites the same issues discussed here.</AbstractText>
<CopyrightInformation>© The Author(s) 2020.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Brownstone</LastName>
<ForeName>Nicholas D</ForeName>
<Initials>ND</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Thibodeaux</LastName>
<ForeName>Quinn G</ForeName>
<Initials>QG</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Reddy</LastName>
<ForeName>Vidhatha D</ForeName>
<Initials>VD</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Myers</LastName>
<ForeName>Bridget A</ForeName>
<Initials>BA</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Chan</LastName>
<ForeName>Stephanie Y</ForeName>
<Initials>SY</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bhutani</LastName>
<ForeName>Tina</ForeName>
<Initials>T</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Liao</LastName>
<ForeName>Wilson</ForeName>
<Initials>W</Initials>
<AffiliationInfo><Affiliation>Department of Dermatology, Psoriasis and Skin Treatment Center, University of California San Francisco, San Francisco, CA USA.</Affiliation>
<Identifier Source="GRID">grid.266102.1</Identifier>
<Identifier Source="ISNI">0000 0001 2297 6811</Identifier>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName>
<AccessionNumberList><AccessionNumber>10.6084/m9.figshare.12063624</AccessionNumber>
</AccessionNumberList>
</DataBank>
</DataBankList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>04</Month>
<Day>16</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Dermatol Ther (Heidelb)</MedlineTA>
<NlmUniqueID>101590450</NlmUniqueID>
</MedlineJournalInfo>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biologics</Keyword>
<Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">Coronavirus</Keyword>
<Keyword MajorTopicYN="N">Infection</Keyword>
<Keyword MajorTopicYN="N">Pandemic</Keyword>
<Keyword MajorTopicYN="N">Psoriasis</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>03</Month>
<Day>25</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>4</Month>
<Day>18</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>aheadofprint</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32300516</ArticleId>
<ArticleId IdType="doi">10.1007/s13555-020-00377-9</ArticleId>
<ArticleId IdType="pii">377</ArticleId>
<ArticleId IdType="pmc">PMC7160052</ArticleId>
</ArticleIdList>
<pmc-dir>pmcsd</pmc-dir>
        <ReferenceList><Reference><Citation>J Am Acad Dermatol. 2008 Jan;58(1):106-15</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17936411</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2005 Jun;152(6):1304-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15948997</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet HIV. 2020 Apr 6;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32272084</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2008 Mar;158(3):558-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18047523</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2008 May 17;371(9625):1665-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18486739</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2005 Oct 15-21;366(9494):1367-74</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16226614</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2003 Nov 20;349(21):2014-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14627786</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Am Acad Dermatol. 2017 Mar;76(3):418-431</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28057361</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Am Acad Dermatol. 2018 Aug;79(2):302-314.e6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29660421</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2014 Jul 24;371(4):326-38</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25007392</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Eur Acad Dermatol Venereol. 2015 Jun;29(6):1082-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25243910</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Am Acad Dermatol. 2018 Aug;79(2):266-276.e5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29660425</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Am Acad Dermatol. 2007 Jan;56(1):e1-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17190617</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2015 Feb;172(2):484-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25132411</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2016 Aug;175(2):273-86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26914406</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>J Am Acad Dermatol. 2017 Mar;76(3):405-417</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28057360</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>N Engl J Med. 2016 Jul 28;375(4):345-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27299809</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2008 May 17;371(9625):1675-84</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18486740</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Arch Dermatol. 2007 Jun;143(6):719-26</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17576937</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2018 Aug 25;392(10148):650-661</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30097359</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2009 Nov;161(5):1190-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19566665</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2012 Jul;167(1):180-90</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22413944</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Br J Dermatol. 2018 Aug;179(2):320-328</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29488226</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
<ReferenceList><Reference><Citation>Lancet. 2017 Jul 15;390(10091):276-288</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28596043</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000065 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000065 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    SrasV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:32300516
   |texte=   Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:32300516" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a SrasV1

This area was generated with Dilib version V0.6.33.
Data generation: Tue Apr 28 14:49:16 2020. Site generation: Sat Mar 27 22:06:49 2021

	Serveur d'exploration SRAS
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration SRAS

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Novel Coronavirus Disease (COVID-19) and Biologic Therapy in Psoriasis: Infection Risk and Patient Counseling in Uncertain Times.

Source :

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki